Show simple item record

dc.contributor.authorMachado, Livia S
dc.contributor.authorKozak, Anna
dc.contributor.authorErgul, Adviye
dc.contributor.authorHess, David C
dc.contributor.authorBorlongan, Cesario V
dc.contributor.authorFagan, Susan C
dc.date.accessioned2013-06-12T15:22:14Z
dc.date.available2013-06-12T15:22:14Z
dc.date.issued2006-07-17
dc.identifier.citationBMC Neuroscience. 2006 Jul 17;7(1):56
dc.identifier.urihttp://dx.doi.org/10.1186/1471-2202-7-56
dc.identifier.urihttp://hdl.handle.net/10724/19790
dc.description.abstractAbstract Background Matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9) are increased in the brain after experimental ischemic stroke in rats. These two proteases are involved with the degradation of the basal lamina and loss of stability of the blood brain barrier that occurs after ischemia and that is associated with thrombolytic therapy in ischemic stroke. Minocycline is a lipophilic tetracycline and is neuroprotective in several models of brain injury. Minocycline inhibits inflammation, apoptosis and extracellular matrix degradation. In this study we investigated whether delayed minocycline inhibits brain MMPs activated by ischemia in a model of temporary occlusion in Wistar rats. Results Both MMP-2 and MMP-9 were elevated in the ischemic tissue as compared to the contra-lateral hemisphere after 3 hours occlusion and 21 hours survival (p < 0.0001 for MMP-9). Intraperitoneal minocycline at 45 mg/kg concentration twice a day (first dose immediately after the onset of reperfusion) significantly reduced gelatinolytic activity of ischemia-elevated MMP-2 and MMP-9 (p < 0.0003). Treatment also reduced protein concentration of both enzymes (p < 0.038 for MMP-9 and p < 0.018 for MMP-2). In vitro incubation of minocycline in concentrations as low as 0.1 μg/ml with recombinant MMP-2 and MMP-9 impaired enzymatic activity and MMP-9 was more sensitive at lower minocycline concentrations (p < 0.05). Conclusion Minocycline inhibits enzymatic activity of gelatin proteases activated by ischemia after experimental stroke and is likely to be selective for MMP-9 at low doses. Minocycline is a potential new therapeutic agent to acute treatment of ischemic stroke.
dc.titleDelayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke
dc.typeJournal Article
dc.date.updated2013-06-07T19:34:00Z
dc.description.versionPeer Reviewed
dc.language.rfc3066en
dc.rights.holderLivia S Machado et al.; licensee BioMed Central Ltd.


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record